ATE415410T1 - Pharmazeutische zusammensetzung zur behandlung von psoriasis und anderen hautkrankheiten - Google Patents
Pharmazeutische zusammensetzung zur behandlung von psoriasis und anderen hautkrankheitenInfo
- Publication number
- ATE415410T1 ATE415410T1 AT02796785T AT02796785T ATE415410T1 AT E415410 T1 ATE415410 T1 AT E415410T1 AT 02796785 T AT02796785 T AT 02796785T AT 02796785 T AT02796785 T AT 02796785T AT E415410 T1 ATE415410 T1 AT E415410T1
- Authority
- AT
- Austria
- Prior art keywords
- psoriasis
- treatment
- denotes
- pharmaceutical composition
- skin diseases
- Prior art date
Links
- 201000004681 Psoriasis Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 208000017520 skin disease Diseases 0.000 title abstract 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 6
- 239000000203 mixture Substances 0.000 abstract 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 abstract 2
- 229960004703 clobetasol propionate Drugs 0.000 abstract 2
- 239000006184 cosolvent Substances 0.000 abstract 2
- 235000011187 glycerol Nutrition 0.000 abstract 2
- 239000006210 lotion Substances 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Natural products C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 229960003387 progesterone Drugs 0.000 abstract 1
- 239000000186 progesterone Substances 0.000 abstract 1
- 230000009291 secondary effect Effects 0.000 abstract 1
- 239000000600 sorbitol Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
- C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
- C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
- C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
- C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Birds (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200102836A ES2188426B1 (es) | 2001-12-12 | 2001-12-12 | Composicion farmaceutica para el tratamiento de la psoriasis y otras dermopatias. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE415410T1 true ATE415410T1 (de) | 2008-12-15 |
Family
ID=8499799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02796785T ATE415410T1 (de) | 2001-12-12 | 2002-12-11 | Pharmazeutische zusammensetzung zur behandlung von psoriasis und anderen hautkrankheiten |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20040225140A1 (de) |
| EP (1) | EP1473300B1 (de) |
| JP (1) | JP2005513139A (de) |
| AT (1) | ATE415410T1 (de) |
| AU (1) | AU2002361265A1 (de) |
| CA (1) | CA2470364A1 (de) |
| DE (1) | DE60230066D1 (de) |
| ES (2) | ES2188426B1 (de) |
| PT (1) | PT1473300E (de) |
| WO (1) | WO2003053991A1 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2898499B1 (fr) * | 2006-03-15 | 2008-11-28 | Galderma Sa | Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant |
| FR2898498B1 (fr) * | 2006-03-15 | 2008-11-28 | Galderma Sa | Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant |
| ES2288133B1 (es) | 2006-06-12 | 2008-09-16 | Maria Cristina Fernandez Rodriguez | Composicion topica para el tratamiento de la psoriasis. |
| ES2334381T3 (es) * | 2006-08-17 | 2010-03-09 | Klever Mode, S.L. | Formulacion farmaceutica para el tratamiento de afecciones en la piel. |
| ES2489615T3 (es) | 2007-12-11 | 2014-09-02 | Apoteknos Para La Piel, S.L. | Uso de un compuesto derivado del acido p-hidroxifenil propionico para el tratamiento de la psoriasis |
| WO2012129305A1 (en) * | 2011-03-23 | 2012-09-27 | Pop Test Cortisol Llc | Combination therapy |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| EP2782584B1 (de) | 2011-11-23 | 2021-06-09 | TherapeuticsMD, Inc. | Natürliche kombinierte hormonersatzformulierungen und -therapien |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
| US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
| KR20170040209A (ko) | 2014-07-29 | 2017-04-12 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 경피 크림 |
| US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
| WO2017037663A1 (en) | 2015-09-02 | 2017-03-09 | Cadila Healthcare Limited | Topical compositions comprising corticosteroids |
| KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
| WO2017173044A1 (en) | 2016-04-01 | 2017-10-05 | Therapeuticsmd Inc. | Steroid hormone compositions in medium chain oils |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3966924A (en) * | 1974-11-13 | 1976-06-29 | Allergan Pharmaceuticals | Composition and method for treating psoriasis |
| JPS56135416A (en) * | 1980-03-27 | 1981-10-22 | Mitsubishi Chem Ind Ltd | Pharmaceutical preparation for skin |
| EP0625045A4 (de) * | 1992-02-07 | 1995-01-18 | Albert M Kligman | Verfahren zur behandlung von entzündlichen dermatosen. |
| WO1994013257A1 (en) * | 1992-12-16 | 1994-06-23 | Creative Products Resource Associates, Ltd. | Occlusive/semi-occlusive lotion for treatment of a skin disease or disorder |
| EP0969847A1 (de) * | 1997-02-20 | 2000-01-12 | Allergan Sales, Inc. | Tazarotene und carticosteroid enthaltende zusammensetzungen zur behandlung von psoriasis |
| US5972920A (en) * | 1998-02-12 | 1999-10-26 | Dermalogix Partners, Inc. | Formulation containing a carrier, active ingredient, and surfactant for treating skin disorders |
-
2001
- 2001-12-12 ES ES200102836A patent/ES2188426B1/es not_active Expired - Lifetime
-
2002
- 2002-12-11 EP EP02796785A patent/EP1473300B1/de not_active Expired - Lifetime
- 2002-12-11 AT AT02796785T patent/ATE415410T1/de active
- 2002-12-11 AU AU2002361265A patent/AU2002361265A1/en not_active Abandoned
- 2002-12-11 ES ES02796785T patent/ES2318061T3/es not_active Expired - Lifetime
- 2002-12-11 CA CA002470364A patent/CA2470364A1/en not_active Abandoned
- 2002-12-11 PT PT02796785T patent/PT1473300E/pt unknown
- 2002-12-11 WO PCT/ES2002/000591 patent/WO2003053991A1/es not_active Ceased
- 2002-12-11 DE DE60230066T patent/DE60230066D1/de not_active Expired - Lifetime
- 2002-12-11 JP JP2003554707A patent/JP2005513139A/ja active Pending
-
2004
- 2004-06-11 US US10/865,991 patent/US20040225140A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT1473300E (pt) | 2009-02-27 |
| ES2318061T3 (es) | 2009-05-01 |
| JP2005513139A (ja) | 2005-05-12 |
| AU2002361265A1 (en) | 2003-07-09 |
| ES2188426A1 (es) | 2003-06-16 |
| ES2188426B1 (es) | 2004-11-16 |
| EP1473300B1 (de) | 2008-11-26 |
| DE60230066D1 (de) | 2009-01-08 |
| CA2470364A1 (en) | 2003-07-03 |
| EP1473300A1 (de) | 2004-11-03 |
| US20040225140A1 (en) | 2004-11-11 |
| WO2003053991A1 (es) | 2003-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60230066D1 (de) | Pharmazeutische zusammensetzung zur behandlung von psoriasis und anderen hautkrankheiten | |
| ATE252529T1 (de) | Colchinolderivate als gefässschädigende mittel | |
| WO2002022598A8 (en) | Quinolinone derivatives as tyrosine kinase inhibitors | |
| AP2001002217A0 (en) | Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids. | |
| MY119181A (en) | Aryl pyrimidine derivatives | |
| ATE504579T1 (de) | Antivirale mittel | |
| DE50102490D1 (de) | Verwendung von substituierten imidazo [1,2-a]pyridin-, -pyrimidin- und -pyrazin-3-yl-amin-derivaten zur herstellung von medikamenten zur nos-inhibierung | |
| TR199901006T2 (xx) | Heterosiklik t�revler. | |
| BR0215240A (pt) | Derivados de calcona e seu uso no tratamento de doenças | |
| DK1392329T3 (da) | Anvendelse af sulodexid til behandling af inflammatorisk tarmsygdom | |
| KR970704452A (ko) | 앨러지성 안질환을 치료하기 위한 독세핀 유도체를 함유하는 국소적 안과용 제제(Topical ophthalmic formulations containing doxepin derivatives for treating allergic eye diseases) | |
| DE69932939D1 (de) | Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen | |
| ATE292117T1 (de) | Zusammensetzungen zur behandlung von hautkrankheiten | |
| ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
| JPH06502161A (ja) | レチノイド浸透作用エンハンサーを含む局所用組成物 | |
| DE50006842D1 (de) | 4-benzylaminochinoline konjugate mit gallensaeure und ihre heteroanalogen, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und deren anwendung | |
| NO975726L (no) | N-Hydroksyurea-derivater som anti-inflammatoriske midler | |
| AU2002333536A1 (en) | Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof | |
| FI932654A0 (fi) | Hydroxamsyraderivat, som hindrar lipoxigenas | |
| PT1337246E (pt) | Utilizacao de compostos de 6-dimetilaminometil-1-fenilciclohexano para terapia da incontinencia urinaria | |
| AP9801235A0 (en) | Erythromycin derivatives. | |
| DE69518258D1 (de) | Kortikoidderivate und pharmazeutische und kosmetische Zusammensetzungen | |
| DE69908855D1 (de) | 9a, 11b-dehydro Derivative von 9-oxime-3-keto-6-0-methylerythromycin | |
| IT1257884B (it) | Formulazioni farmaceutiche per il trattamento di malattie periferiche vascolari a base di vincamina o di un suo sale farmaceuticamente accettabile. | |
| MY133957A (en) | "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor" |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1473300 Country of ref document: EP |